pragma.vision Technology observatory

Verification register Bio, Health & Neuro

Living definition

What is Gedatolisib (Revtorpyk)?

Drug Discovery & Development Bio, Health & Neuro

As of
2026-07-23
Revision
2026-07-26.1
Method
v1.3.0

Definition

The term, in context

AI-assisted draft · approved dataset

Gedatolisib (Revtorpyk) is a small-molecule inhibitor targeting the PI3K and mTOR signalling pathway, developed as a treatment for advanced breast cancer.

Live readiness status

Status as of the current dateline

AI-assisted assembly · derived results

As of 2026-07-23, verified readiness is 61 (claimed 90, reported 76, gap 29) — Critical evidence strength; current signals suggest Adopt with guardrails.

The readiness fact belongs to the canonical Readiness Verdict for Gedatolisib (Revtorpyk).

Dataset approval

Human editorial release

pragma.vision editorial — standing authorization (operator dev@soft.house, 2026-07-17)

Dataset
2026-07-26.1
Hash
sha256:a5b861157968f418e08e6a08da71c7cfd4c6b23c3955d9d77ad5bcf67b9e2482
Approved
2026-07-26

Your opinion

Tell us anything.

What works, what doesn't, what's missing — especially about our watches, lenses, and the register itself. Anonymous is fine; leave an email if you'd like a reply.